Cabozantinib,Nivolumab,Ipilimumab
BMS
['nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo']
cabozantinib plus nivolumab and ipililumab improves pfs in advanced rcc subgroups #urology #urologist #gu23 #kidneycancer 
The Leading News Source for Urologists - https://t.co/hDKngB4IyE
Expert clinical analysis. Practice advice. Policy perspectives.